"Patients with Huntington's disease are known to have imbalances ... MD of 0.10 points Symbol digit modalities test: MD of 0.33 points Post hoc analyses did not show significant beneficial effects ...

Northern Scotland has one of the highest rates of Huntington’s disease globally, according to new research from the ...

Qure (QURE) stock surges 39% as FDA grants Breakthrough Therapy designation for AMT-130, a gene therapy for Huntington’s disease. Read more here.

The US Food and Drug Administration (FDA) has awarded breakthrough therapy designation to uniQure's AMT-130 for treating Huntington's disease, a rare neurodegenerative condition. This designation ...

uniQure's AMT-130 receives Breakthrough Therapy designation from FDA for Huntington's disease, based on promising clinical trial data. uniQure N.V. announced that the U.S. FDA has granted ...

Sage Therapeutics’ SAGE phase II study evaluating its neuropsychiatric candidate, dalzanemdor (SAGE-718), for treating cognitive impairment (CI) associated with Huntington’s Disease (HD ...

This type of medication can help manage the uncontrolled movements that can occur with Huntington’s disease. Huntington’s disease is a neurodegenerative disorder that causes a progressive ...